BioCryst Pharmaceuticals (NASDAQ: BCRX) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare BioCryst Pharmaceuticals to related companies based on the strength of its analyst recommendations, institutional ownership, risk, earnings, dividends, valuation and profitability.
Insider & Institutional Ownership
84.7% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.6% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a summary of recent ratings and recommmendations for BioCryst Pharmaceuticals and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioCryst Pharmaceuticals Competitors||960||3412||11912||239||2.69|
BioCryst Pharmaceuticals currently has a consensus price target of $9.14, indicating a potential upside of 61.53%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.03%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe BioCryst Pharmaceuticals is more favorable than its peers.
Valuation & Earnings
This table compares BioCryst Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BioCryst Pharmaceuticals||$26.35 million||-$55.14 million||-8.84|
|BioCryst Pharmaceuticals Competitors||$290.27 million||$35.99 million||52.35|
BioCryst Pharmaceuticals’ peers have higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares BioCryst Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioCryst Pharmaceuticals Competitors||-6,408.55%||-84.01%||-35.63%|
Risk and Volatility
BioCryst Pharmaceuticals has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals’ peers have a beta of 2.51, meaning that their average stock price is 151% more volatile than the S&P 500.
BioCryst Pharmaceuticals peers beat BioCryst Pharmaceuticals on 8 of the 13 factors compared.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.